| 60.83 0.21 (0.35%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 77.52  |
1-year : | 82.56 |
| Resists | First : | 66.37 |
Second : | 70.69 |
| Pivot price | 63.33 |
|||
| Supports | First : | 59.38 |
Second : | 49.41 |
| MAs | MA(5) : | 61.7 |
MA(20) : | 64.38 |
| MA(100) : | 65.55  |
MA(250) : | 55.76 |
|
| MACD | MACD : | -2.2 |
Signal : | -2 |
| %K %D | K(14,3) : | 12.4 |
D(3) : | 14.9 |
| RSI | RSI(14): 35.4 |
|||
| 52-week | High : | 82.04 | Low : | 41.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PCVX ] has closed above bottom band by 11.6%. Bollinger Bands are 31.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 61.98 - 62.28 | 62.28 - 62.54 |
| Low: | 58.69 - 59.03 | 59.03 - 59.32 |
| Close: | 60.31 - 60.85 | 60.85 - 61.31 |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Wed, 10 Apr 2024
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says - Vaxcyte (NA - Benzinga
Wed, 10 Apr 2024
Needham & Company LLC Reaffirms Buy Rating for Vaxcyte (NASDAQ:PCVX) - MarketBeat
Wed, 20 Mar 2024
Insider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 Shares - Yahoo Finance
Fri, 01 Mar 2024
PCVX Stock Quote Price and Forecast - CNN
Wed, 28 Feb 2024
Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call Transcript - Yahoo Finance
Wed, 28 Feb 2024
Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 108 (M) |
| Shares Float | 99 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 96.7 (%) |
| Shares Short | 8,260 (K) |
| Shares Short P.Month | 8,460 (K) |
| EPS | -4.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24.3 % |
| Return on Equity (ttm) | -36.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -297 (M) |
| Levered Free Cash Flow | -202 (M) |
| PE Ratio | -14.7 |
| PEG Ratio | 0.4 |
| Price to Book value | 4.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -22.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|